cyrilzakka/clinical-trials huggingface dataset:
Virtual Reality versusTask-oriented for Gait in CP

The children with hemiplegic cerebral palsy had a longer gait cycle, slower walking speed, and longer support phase than did the healthy children. The support phase was longer than the swing phase in the children with hemiplegic cerebral palsy

This research aims to evaluate the effect of virtual reality (VR) games on balance recovery of children with cerebral palsy (CP) by quantitatively synthesizing the existing literature, and to further determine the impact of VR game intervention (the duration of each intervention, intervention frequency, intervention cycle, and total intervention time) on the balance recovery of children with CP.

A high-intensity task-oriented training programme designed to improve hemiplegic gait and physical fitness was feasible in the present study and the effectiveness exceeds a low intensity physiotherapy-programme in terms of gait speed and walking capacity in hemiplegic cp. In a future study, seems appropriate to additionally use measures to evaluate physical fitness and energy expenditure while walking.

Eligibility Criteria:
Inclusion Criteria:

1. Their age will ranging from 7 to 9 years.
2. Children participated in this study will from both sexes.
3. Their degree of spasticity will ranged from mild to moderate according to Modified Ashworth Scale.
4. All children will able to walk supported or unsupported by the therapist.
5. Children will able to follow the instructions during testing and training.
6. All children had no fixed contractures or deformities at the lower limb.

Exclusion Criteria:

1. Children with visual or auditory problems.
2. Children with history of epilepsy.
3. Children with structural joints deformities of the lower limbs.
4. Children with history of surgical interference in lower limbs less than one year.
5. Children with convulsions and fixed contractures.
6. Uncooperative children.
Evaluating Mindfulness-Based Interventions With New Fibromyalgia Patients

The purpose of this study is to study the feasibility of a wearable brain sensing wellness device to provide mindfulness training to fibromyalgia patients who have failed medical therapy.

All study participants will receive a wearable brain sensing wellness device, and demonstration of the mindfulness sessions. Participants will be asked to complete study surveys/questionnaires. During the first part of study, participants will be asked to complete the intervention. After completion of the intervention they will enter a follow-Up Phase, where they will be contacted and asked to complete surveys and gauge satisfaction with the study.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older at time of consent.
* Diagnosed with Fibromyalgia.
* Not pregnant by subject self-report at time of consent.
* Have the ability to provide informed consent.
* Have the ability to complete all aspects of this trial.
* Have access to a iPhone, iPad, Android device.
* Has no contraindicating comorbid health condition as determined by the clinical investigators.

Exclusion Criteria:

* Used or been enrolled in any treatments for fibromyalgia, or pain within the past 30 days.
* Used an investigational drug within the past 30 days.
* Currently (within the past 3 weeks) been practicing mindfulness training on a weekly/regular basis.
* Currently (within the past 3 weeks) been undergoing an additional program (e.g. CAM) to improve quality of life.
* Currently (within 3 weeks) been enrolled in another clinical or research program (e.g. CAM) which intervenes on the patients' QOL, or stress.
* An unstable medical or mental health condition as determined by the physician investigator.
Al to Improve the Diagnosis of Rare Rheumatic Diseases

This trial aims to assess the impact of providing medical students with access to ChatGPT, a state-of-the-art large language model, in comparison to conventional diagnostic decision support tools, on their diagnostic accuracy for rare rheumatic diseases.

Advanced artificial intelligence (AI) technologies, particularly large language models such as OpenAI's ChatGPT, hold significant potential for enhancing medical decision-making. While ChatGPT was not specifically designed for medical applications, it has shown utility in various healthcare scenarios, including answering patient inquiries, drafting medical documentation, and aiding consultations. Despite these advancements, its role in supporting diagnostic reasoning-especially among less experienced medical students-and for complex rare diseases remains underexplored.

Diagnostic reasoning is a multifaceted process that combines pattern recognition, knowledge synthesis, and probabilistic thinking. Tools like ChatGPT could potentially alleviate cognitive burden, enhance diagnostic accuracy, and ultimately accelerate the diagnosis for rare diseases. However, ChatGPT is not tailored for diagnostic reasoning and lacks comprehensive validation in this domain. Additionally, it is susceptible to generating misinformation or plausible-sounding but inaccurate responses, which may hinder rather than support clinical decision-making. Therefore, understanding how medical students utilize such AI tools is essential before they are integrated into educational or clinical workflows. This study will also assess a standardized prompt to facilitate ChatGPT usage and will give students direct access to enable a realistic scenario.

This study will investigate the impact of ChatGPT on the diagnostic accuracy of medical students when tackling cases of rare rheumatic diseases. Participants will be randomized into two groups: one with access to ChatGPT and one using conventional diagnostic tools. Each participant will analyze diagnostic cases by providing up to 5 differential diagnoses and and rating the diagnostic confidence. Independent reviewers, blinded to group allocation, will evaluate the accuracy and quality of their responses. This study hence aims to provide insights into the potential benefits and limitations of integrating AI tools like ChatGPT.

Eligibility Criteria:
Inclusion Criteria:

* Medical students having started with clinical subjects (Internal medicine)

Exclusion Criteria:

* Not being a medical student
Tolerance, Pharmacokinetics and Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)

The purpose of this study is to assess the MTD, Pharmacokinetics and preliminary efficacy of T0001 in Rheumatoid Arthritis.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-45 years old;
* Diagnosed with active RA;
* DMARDs therapy must not be used for at least 28 days prior to baseline;
* If a patient has received NSAIDs，current NSAIDs therapy must have been at a stable dose for at least 28 days prior to baseline;
* Patient or patient's legal representative able to give written informed consent for participation in the trial.

Exclusion Criteria:

* Acute or chronic infection, or history of active tuberculosis;
* History of diseases of central nervous system, cardiovascular system, kidney, liver ( specified liver function index), digestive system, respiratory system , metabolism system;
* Patients who have a high risk of infection (with a current infectious disease, a chronic infectious disease, a history of serious infectious disease);
* Patients who use 5 Unit doses tuberculin skin test are positive( 48-72 hour scleroma reading≥5mm);
* Patients who currently have, or who have a history of, malignancy;
* Patients who lack of understanding ,communication or collaboration, and can't comply with the protocols;
* Female patients who are breastfeeding or pregnant, who are of childbearing potential.
The Diagnostic Value of Contrast-enhanced Ultrasound in Acute Kidney Injury in ICU

The goal of this observational study is to quantitatively assess the renal microcirculation changes by contrast-enhanced ultrasound (CEUS) and to obtain systemic hemodynamic information by ultrasound Doppler at the same time, to analyze the relationship between renal microcirculation changes and systemic hemodynamic changes, and to explore the diagnostic value of CEUS in critically ill acute kidney injury.

The main questions it aims to answer are:

1. To explore the quantitative parameters of contrast-enhanced ultrasound which can reflect the changes of renal microcirculation。
2. To explore the relationship between renal microcirculation and systemic hemodynamics。
3. To explore the value of quantitative evaluation of renal microcirculation changes by contrast-enhanced ultrasound in the diagnosis of acute kidney injury

Eligibility Criteria:
Inclusion Criteria:

* Age\>18 years old
* First admission to ICU \< 24h after admission and expected ICU stay ≥48 hours
* Acute kidney injury risk factors (KDIGO 2012)
* Contrast-enhanced ultrasound

Exclusion Criteria:

* Known severe chronic kidney disease (CKD≥ stage 4) or undergoing hemodialysis treatment
* Kidney transplantation or renal malignancy
* Terminal stage of malignant tumor
* Pregnancy
* Renal artery stenosis or renal vein thrombosis
* The quality of CEUS images is poor, and quantitative analysis cannot be performed
Clinical Evaluation of the Picosure Laser for the Treatment of Unwanted Tattoos

The purpose of this study is to evaluate the PICOSURE Laser System for the treatment of unwanted tattoos


Eligibility Criteria:
Inclusion Criteria:

1. Is a healthy non-smoking (must have quit 6 months prior) male or female between 18 and 65 years old.
2. Is willing to consent to participate in the study.
3. Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits
4. Has unwanted non-cosmetic tattoo containing red ink, that has not previously been treated, and wishes to undergo laser treatment

Exclusion Criteria:

1. The subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
2. The subject is hypersensitive to light exposure OR takes photo sensitized medication.
3. The subject has active or localized systemic infections.
4. The subject has a coagulation disorder or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy {greater than 81 mg per day}).
5. The subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
6. The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 3 months prior to entering this study.
7. The subject has used Accutane within 6 months prior to enrollment.
8. The subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial.
9. The subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate).
10. The subject has a history of keloids.
11. The subject has evidence of compromised wound healing.
12. The subject has a history of basal cell carcinoma, squamous cell carcinoma or melanoma.
13. The subject has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications or has an autoimmune disorder.
Benzoates - an Obesogenic Endocrine Disrupting Chemical

The benzoic acid derivatives sodium and potassium benzoate are preservatives that are commonly added to food and beverages to inhibit microbial growth and prevent spoilage. In the US the major source of benzoate intake is beverages. Studies have shown that piglets or chicks fed low levels of benzoic acid have greater feed efficiency and gain more weight than control fed animals. It has also been shown that benzoic acid inhibits the release of a key metabolic hormone, leptin, from isolated adipocytes (fat cells). Inadequate leptin levels result in increased appetite, decreased metabolic rate, weight gain, insulin resistance and increased diabetes risk.

The primary aim of the proposed research is to directly determine if benzoate consumption in human volunteers results in lower levels of leptin, decreased metabolic rate and increased insulin resistance. If so this would implicate benzoic acid as an obesogen and would help inform more effective approaches to obesity prevention and treatment. A secondary aim of the study is to establish a connection between benzoate exposure and biomarkers in urine that can be used to help treat obese patients.

Our hypothesis is that benzoic acid is an obesogenic xenobiotic that attenuates the leptin signaling pathway resulting in lower metabolic rate and hence a propensity to weight loss non-responsiveness.

This hypothesis will be addressed in this pilot project via the following Specific Aims:

Aim 1. Determine if dietary benzoate attenuates leptin levels and metabolic rate in human subjects. Twenty heathy adolescents and young adults (age 18-25 yrs.) who are either overweight (BMI 25-29.9) or obese (BMI ≥ 30) will be studied. Following a 14 day period of avoiding benzoate containing beverages (washout period) subjects will then consume 36 oz./day of benzoate containing beverages (\~ 3.9 - 4.5 mg benzoate/kg body weight per day exposure) for 7 days (exposure period). Fasting plasma samples will be collected pre and post-exposure and leptin, adiponectin, insulin and glucose levels will be compared. Indirect calorimetry will be used to compare resting energy expenditure pre-and post-exposure.

Aim 2. Validate the use of urinary hippurate and glycine to assess benzoate exposure. An early morning void urine samples will be collected pre-and post-exposure. Non-targeted NMR-based metabolomics analysis will be used to compare changes in individual subject's urinary metabolome using pre- and post-exposure as the "phenotypic" anchors.

Eligibility Criteria:
Inclusion Criteria:

* Young adult (18-30 yrs)
* Healthy non-smoker
* Either overweight (BMI \>25 but \<30) or obese (BMI \>30)
* Has or can obtain transportation to study site
* Able to provide written consent in English

Exclusion Criteria:

* Metabolic disease

  1. Diabetes mellitus
  2. Hypothyroidism
* Use of medication that may influence metabolism

  1. Anti-hyperglycemic agents
  2. Thyroid hormone
  3. Stimulants for ADD/ADHD
  4. Atypical anti-psychotics
  5. Weight loss medications
* Benzoate sensitivity
* Known pregnancy
Patient-Reported Outcomes in Adults With Congenital Heart Disease

The purpose of this study is to examine the differences in perceived health, psychosocial functioning, behavioral outcomes and quality of life of adults with congenital heart disease who are living in different areas of the world, and how these differences can be understood (e.g., differences in sense of coherence or illness perceptions).


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with congenital heart disease, defined as: a gross structural abnormality of the heart or intra-thoracic great vessels that is actually or potentially of functional significance (including mild, moderate, and severe heart defects)
* 18 years of age or older
* Diagnosed under the age of ten, i.e. before adolescence
* Continuing follow-up at an adult congenital heart disease center or included in a national/regional registry
* Physical, cognitive, and language abilities to complete self-report questionnaires

Exclusion Criteria:

* Prior heart transplantation
* Isolated pulmonary hypertension
* Syndromes affecting cognitive abilities
Monitoring Bleeding of Patients Using NOAC Anticoagulation Therapy in Proximal Femoral Fracture Internal Fixation Surgery Without Waiting. We Measure Bleeding in Surgery and the Levels of Noac Drug in Blood. We Will Try to Compare to Regular Pateints Later

until today we waited at least 24 hours before surgery of femoral neck fractures in patients who take anticouagolation . in our new reasearch we belive that patients who take NOAC can go under surgery earlier with minimal risk


Eligibility Criteria:
Inclusion Criteria:

above 18 y.o femoral neck fracture NOAC capable of making inform consent primary surgery

-

Exclusion Criteria:

* under 18 y.o
* anti platelet therapy (aspirin is not included)
* creatinine clearance under 50
* active anti cancer therapy
* ITP patients
* non capable of making inform consent
* patients which decide not to proceed with the expeirment
Utility of Dynamic Variables Measured by Calibrated Pulse Contour Analysis of Oesophageal Doppler Monitor for Predicting Fluid Responsiveness During Robot-Assisted Laparoscopic Prostatectomy

Robot-assisted laparoscopic prostatectomy (RALP) is widely performed due to its many advantages, including a reduced need for blood transfusion and fewer surgical complications compared with conventional open prostatectomy. As this approach is also recommended in elderly patients with serious comorbidities, optimal fluid therapy guidance during this procedure is important.

Dynamic variables such as pulse pressure variation (PPV) and stroke volume variation (SVV) are used to predict and guide fluid therapy during controlled ventilation. These variables arise from heart-lung interactions during positive pressure ventilation, which influence left ventricular stroke volume (SV). RALP requires carbon dioxide insufflation and the steep Trendelenburg position to optimise surgical conditions, and can reduce cardiac output and respiratory compliance. Accordingly, the usefulness of PPV and SVV, which are affected by changes in intrathoracic pressure, in predicting fluid responsiveness during laparoscopic surgery under these conditions may be questioned. A recent study established that PPV and SVV derived by uncalibrated pulse contour analysis had a relatively poor capacity to predict fluid responsiveness during laparoscopy on dynamic preload indices. In contrast, another study SVV measured by oesophageal Doppler monitor (ODM) could predict fluid responsiveness during laparoscopic surgery.

The CardioQ-ODM+ combines the proven ODM Doppler measurement of blood flow with pulse contour analysis, which is quickly and easily calibrated from the Doppler signal. We hypothesized that PPV and SVV measured by calibrated pulse contour analysis would be a good indicator of fluid responsiveness during laparoscopy with pneumoperitoneum.

The primary objective of this study was to demonstrate that PPV and SVV measured by calibrated pulse contour analysis of CardioQ-ODM+ can accurately predict fluid responsiveness during RALP, which involves both pneumoperitoneum and the Trendelenburg position. Investigators also assessed the capacity of other dynamic variables (SPV \[systolic pressure variation\], and SVV determined by ODM Doppler flow, dynamic elastance \[PPV/SVV\] and corrected flow time \[FTc\]) to predict fluid responsiveness during RALP.


Eligibility Criteria:
Inclusion Criteria:

* patients undergoing elective robot-assisted laparoscopic prostatectomy

Exclusion Criteria:

* patients with a BMI \> 30 or , \< 15 kg/m2 valvular heart disease left ventricular ejection fraction \< 50% a history of lung disease preoperative arrhythmia contraindications to OED monitoring probe insertion (i.e. oesophageal stent, carcinoma of the oesophagus or pharynx, previous oesophageal surgery, oesophageal stricture, oesophageal varices, pharyngeal pouch, and severe coagulopathy)
Transapical Beating-heart Myectomy for the Treatment of Apical Hypertrophic Cardiomyopathy

The primary purpose of this study is to evaluate the feasibility, the safety and the efficacy of the transapical beating-heart myectomy for the treatment of apical hypertrophic cardiomyopathy. This is a prospective, single-arm, single-center study.


Eligibility Criteria:
Inclusion Criteria:

1. Patients who were diagnosed as apical hypertrophic cardiomyopathy, with maximal apical wall thickness ≥ 15 mm.
2. Patients with heart function of New York Heart Association ≥ class II.
3. Patients with drug-refractory symptoms or intolerable to pharmaceutical therapies.
4. Patients who was informed the nature of the clinical trial, consented to participate in all of the activities of the clinical trial, and signed the informed consent form.

Exclusion Criteria:

1. Patients who were pregnant.
2. Patients who had concomitant diseases such as intrinsic valvular disease or coronary artery disease that needed open-chamber cardiac surgery.
3. Patients who had severe heart failure with left ventricle ejection fraction \< 40%.
4. Patients whose estimated life expectancy \< 12 months.
5. Patient who were non-compliant.
6. Patients under circumstances which were considered not suitable or prohibitive for participating the clinical trial at the discretion of the attending medical team and the researchers.
Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b

This study will investigate safety and reactogenicity of a monovalent conjugated vaccine against Haemophilus influenzae type b in healthy children


Eligibility Criteria:
Inclusion Criteria:

* Infants of either sex, aged 16 - 20 months / 2 - 4 months
* in good health as determined by: medical history physical examination clinical judgment of the investigator;
* available for all visits scheduled in the study and able to comply with all study regulations;
* written informed consent obtained, from at least one parent or legal guardian

Exclusion Criteria:

* parent or legal guardian is unwilling or unable to give written informed consent to participate in study;
* infants who presented a previous disease potentially related to Haemophilus influenzae type b;
* infants who had household contact and/or intimate exposure in the previous 30 days to an individual with ascertained Haemophilus influenzae type b disease;
* infants who have received any other Haemophilus influenzae type b immunization dose before (for 16-20 months old children who have received a booster vaccination already);
* premature (before 37th week of gestation) or birth weight less than 2500 g;
* history of anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;
* fever ≥38.0 °C (axillary body temperature) and/or significant acute or chronic infection requiring systemic antibiotic or antiviral therapy within the past 7 days before enrollment;
* subjects with any serious chronic disease such as cardiac, neurological, metabolic, hematologic, or neoplastic disease;
* known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder;
* subjects with any neurological disorder, e.g., epilepsy or history of seizure disorder;
* subjects with a clinically significant genetic anomaly;
* treatment with corticosteroids or other immunosuppressive drugs;
* treatment with parenteral immunoglobulin preparation, blood products, and/or plasma derivatives (or: within the past 3 months - applicable for children 16 - 20 months);
* any vaccination administered within 2 weeks (14 days) before enrollment;
* participation in any other investigational trial simultaneously;
* planned surgery during the study period;
* any condition, which, in the opinion of the investigator, might interfere with the evaluation of the study objective